Skip over navigation | Sla menu over

News

Recent news

Horizon Discovery Signs License Agreement with ProteoNic B.V. for the Provision of Expression Vectors Alongside Horizon Bioproduction Cell Lines
7 Jun 2016 Recent news victor schut

• Horizon’s GS null cell lines now include ProteoNic CHOGUN vector as standard
• Inclusion of vector provides customers with complete biomanufacturing platform

Cambridge, UK, 7 June 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including bioproduction cell lines, today announces it has entered into a non-exclusive Licensing Agreement with ProteoNic B.V. to provide the CHOGUN expression vector to customers alongside Horizon’s HD-BIOP3 GS Null CHO cell line as standard, providing a powerful and complete biomanufacturing platform.

Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology
9 Sep 2015 Recent news victor schut


Morgan Hill, Ca, USA - 9 September 2015.   Aragen Bioscience, Inc. (Aragen) announces that it has entered into an agreement with ProteoNic Biotechnology BV (ProteoNic) for the commercial use of ProteoNic’s 2G UNic™ recombinant protein production technology. Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods. In combination with the value added services offered by Aragen, access to the technology will allow Aragen’s clients to increase manufacturing efficiency and reduce cost of goods for recombinant biologicals.

ProteoNic awarded European FP7 funding in EUR 9 million project
23 Jan 2014 Recent news Marlies Louter

Leiden, the Netherlands, 23 January 2014 – ProteoNic BV, a leading provider of technology for recombinant protein production, will participate in an international consortium that has been awarded a EUR 7 million Framework Program 7 (FP7) Research Grant by the European Commission. The FP7 grant will support the development of novel enzymes for efficient production of antioxidants.

Update - ProteoNic 2G UNic vectors and plug-in elements
21 Nov 2013 Recent news Marlies Louter

2G UNic™ vectors and plug-in elements for protein production

 

ProteoNic has relocated its headquarters
20 Mar 2013 Recent news Marlies Louter

ProteoNic has relocated its headquarters, expanding its facilities at the Leiden Bio Science Park, the Netherlands

ProteoNic and Oxford Expression Technologies sign UNic™ license for use in flashBAC™
7 Mar 2013 Recent news Marlies Louter

 

Leiden, Netherlands/Oxford, United Kingdom, March 7, 2013 – Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have extended their partnership by signing a commercial license agreement. OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services. ProteoNic will provide technical support. Financial terms include upfront and royalty payments.

Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13 and are available for partnering meetings.
 

ProteoNic announces closing of financing round
28 Sep 2011 Recent news proteonicnl proteonicnl

 

 

 

24 items